TrialStudy to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
Trial details
- Registry ID
- NCT04705597
- Phase
- Phase 2
BIOA
BioAge Labs, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory FailureNCT04705597 | BIOA | Phase 2 | Terminated | 2022-04-20Actual |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverNCT06515418 | BIOA | Phase 2 | Terminated | 2025-02-06Actual |
| A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727 | BIOA | Phase 2 | Active not recruiting | 2026-11-30Estimated |
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
Trial details
- Registry ID
- NCT06515418
- Phase
- Phase 2
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Trial details
- Registry ID
- NCT07656727
- Phase
- Phase 2
Latest recorded trial changes
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727 · BioAge Labs, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting